Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI)

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 30, 2026

Primary Completion Date

August 31, 2028

Study Completion Date

August 31, 2028

Conditions
Triple Negative Breast Cancer
Interventions
DRUG

[18F]FMISO-PET with contrast-enhanced MRI

Triple negative breast cancer patients that are planning to undergo immunotherapy and consent to this study will have 3 imaging visits. Imaging visit 1 will take place before the patients start immunotherapy. Imaging Visit 2 will take place after the patient completes the 1st cycle of immunotherapy and before they start their 2nd cycle. Imaging Visit 3 will take place when the patient completes the 2nd cycle of immunotherapy and before they start the 4th cycle.

Trial Locations (1)

35249

UAB, Birmingham

All Listed Sponsors
lead

University of Alabama at Birmingham

OTHER

NCT04861077 - Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI) | Biotech Hunter | Biotech Hunter